论文部分内容阅读
目的:探讨沙利度胺联合VAD方案治疗多发性骨髓瘤(MM)的疗效。方法:选择我院收治的MM患者42例进行沙利度胺联合VAD方案治疗,观察治疗前后骨髓增生情况以及骨髓瘤细胞数量、血红蛋白、β2-微球蛋白等各项检测指标的变化。结果:42例患者中总有效率为83.33%,治疗后患者血红蛋白显著高于治疗前,差异有统计学意义(P<0.05)。骨髓浆细胞百分比、β2-微球蛋白、肌酐显著低于治疗前,差异有统计学意义(P<0.05)。结论:沙利度胺联合VAD方案治疗MM疗效显著,且不良反应少、耐受性好、给药方便,值得临床推广。
Objective: To investigate the efficacy of thalidomide combined with VAD regimen in the treatment of multiple myeloma (MM). METHODS: Twenty-two patients with MM treated in our hospital were treated with thalidomide and VAD regimen. The changes of myelodysplastic and myeloma cell numbers, hemoglobin, β2-microglobulin and other indicators before and after treatment were observed. Results: The total effective rate was 42.33% in 42 patients. After treatment, hemoglobin was significantly higher than that before treatment. The difference was statistically significant (P<0.05). The percentage of bone marrow plasma cells, β2-microglobulin, and creatinine were significantly lower than before treatment, and the difference was statistically significant (P<0.05). Conclusion: Thalidomide combined with VAD regimen is effective in the treatment of MM, with fewer adverse reactions, good tolerability, and convenient administration, and is worthy of clinical promotion.